Bleeding Disorders affects a significant proportion of the population worldwide. Hemophilia A and B and Von Willebrand’s disease are common bleeding disorders that occur due to Coagulation factor Deficiencies. As per the Delveinsght, the total Hemophilia A prevalent population in the seven major markets (i.e the United States, Italy, Spain, Germany, the United Kingdom and Japan) was 43,243 in 2020, which is expected to rise during the study period. Similarly, the total Hemophilia B prevalent population in the 7MM in 2020 was 10,739 while the total diagnosed Von Willebrand disease prevalent population in 7MM was observed to be 33,758.
The limited diagnosis and treatment option for Bleeding Disorders affect the quality of life of the patients and also life expectancy. However, to fulfil the unmet need in the Bleeding Disorders treatment market, companies such as BioMarin Pharmaceutical, Biotest AG, Bristol Myers Squibb, Catalyst Biosciences, CSL Behring, GC Pharma, Grifols, Kezar Life Sciences, LFB, Novo Nordisk, Octapharma, Pfizer, Principia Biopharma, Protalex, Sangamo Therapeutics, Sanofi, Spark Therapeutics, UCB Biopharma SPRL, uniQure, and others are diligently working toward the development of novel therapeutic options. Similarly, in the coming years the launch of emerging therapies, rising awareness, increasing healthcare spending, and regulatory approval will stimulate the Bleeding Disorders market growth.
For more details, visit: Bleeding Disorders Therapeutics Market